New Aspects of Tyrosine Kinase Inhibitors Marcia S. Brose MD PhD Associate Professor
|
|
- Lydia Douglas
- 5 years ago
- Views:
Transcription
1 New Aspects of Tyrosine Kinase Inhibitors Marcia S. Brose MD PhD Associate Professor Department of Otorhinolaryngology: Head and Neck Cancer Department of Medicine, Division of Hematology/Oncology Abramson Cancer Center The University of Pennsylvania Philadelphia, PA
2 Disclosures Companies: AstraZeneca, Bayer/Onyx, Eisai, Exelixis, Novartis, Roche/Genentech, Loxo, Oxigene Relationships: Advisory board consultant, honoraria, research grants, and primary investigator As there are currently two FDA approved agents for progressive DTC other than doxorubicin and sorafenib, all the remaining agents I will mention will be in the context of a clinical trials 2
3 Genetics of Differentiated Thyroid Cancer: aberrant intracellular signaling Poorly differentiated RAS (25 30%) TP53 (20 30%) CTNNB1 (10 20%) BRAF (10 15%) Follicular Mutations in 70 75% RAS (40 50%; lower in oncocytic) PAX8/PPARγ (30 35%; lower in oncocytic) TP53 (21%) PTEN (8%) PIK3CA (7%) BRAF (2%) Oncocytic Conventional Papillary DTC Anaplastic Medullary Papillary Mutations identified in ~70% BRAF a (40 50%) RAS b (7 20%) RET/PTC (clonal; 10 20%) EGFR (5%) TRK (<5%) PIK3CA (2%) a BRAF mutations are mostly V600E; 1 2% are K601E and others b RAS includes N-, H-, and K-RAS (predominantly NRAS and HRAS codon 61) Nikiforov YE et al. Arch Pathol Lab Med 2011;135:569 77; COSMIC database Catalog of Somatic Mutations in Cancer
4 Kinase Inhibitors ATP KI KI ATP Y P Activated pathway Cancer Y Activated Pathway Cancer RET, BRAF.. inhibition VEGFR inhibition Tumor growth Tumor angiogenesis
5 Targets of Kinase Inhibitors Compound Name VEGFR BRAF PDGFR KIT RET Other Sorafenib FLT-3 Sunitinib FLT-3 Axitinib Pazopanib Vandetanib + + EGFR Cabozantinib + + C-MET Lenvatinib FGFR Vemurafenib BRAF V600E DTC, differentiated thyroid cancer; EGFR, endothelial growth factor receptor; FGFR, fibroblast growth factor receptor; PDGFR, platelet-derived growth factor receptor; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor. 1. Perez CA, et al. Biologics. 2012;6: Pacini F. Expert Rev Endocrinol Metab. 2012;7:
6 DECISION and SELECT: Next Steps Patients on the SELECT had a much shorter PFS on the placebo arm than DECISION, suggesting that the populations are not the same in growth rate. A direct comparison in the same population would be useful to compare efficacy. Use of RECIST 1.1 vs 1.0 for study entry Use of central review on SELECT resulted in almost 1/3 rd of patients deemed eligible by investigators being deemed ineligible (selection for more aggressive disease) Central review of pathology to determine number of Poorly Differentiated subtype was done on DECISION but not on SELECT Lenvatinib had significantly higher number of deaths related to drug and incidence of thromboembolic events and hemorrhages. If FDA approved, safety and efficacy of the two agents when used sequentially will need to be determined, ideally by a sequencing study (A then B vs B then A)
7 Rational for the Addition of Everolimus to Sorafenib in Sorafenib Failures Radiographically, patients progression is not uniform and many nodules are stable. At the tissue level, there is heterogeniety, suggesting that sorafenib is controlling some of the tumor growth, even at the time of progression. Patients who are progressing say they feel better if they stay on the sorafenib. One patient switched to mtor inhibitor responded in the progressing nodules but failed due to progression of nodules previously stabilized on sorafenib Development of underlying resistance pathways likely differ based on heterogeneity among disease sites
8 Analysis of 40 pts on UPCC0330 Yarchoan et al: Low nuclear pakt staining was associated with decreased response (paper submitted)
9 100% Response by Nuclear pakt Expression Percent of Patients 80% 60% 40% 20% P<0.01 Partial Response Stable Disease Progressive Disease 0% Above Average Below Average Partial Response 18.2% 70.6% Stable Disease 72.7% 29.4% Progressive Disease 9.1% 0.0% Nuclear pakt Expression
10 UPCC 19309: Everolimus Plus Sorafenib for DTC Patients Who Progress on Sorafenib Alone Eligibility criteria Metastatic, iodinerefractory thyroid cancer Life expectancy > 3 months PD on sorafenib ECOG PS 0-2 Good organ and bone marrow function n = 35 Sorafenib + everolimus Intrapatient dose escalation Primary endpoints RECIST PFS Response rate 35 Patients accrued PFS 13.9 months (embargoed) DTC, differentiated thyroid cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; PD, progressive disease; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors. ClinicalTrials.gov identifier # NCT
11 UPCC 19309: Everolimus + sorafenib for patient that progressed on sorafenib alone PFS 13.9 months Series Months
12 UPCC 19309: Everolimus + sorafenib for patient that progressed on sorafenib alone Study ID Date on Study Drug End of study Date End of Study Visit Date Total time On Studydays Time in months Highest Dose of Highest Dose of Everolimus Sorafenib /27/2011 7/10/2012 7/10/2012 PD mg 800 mg /27/2011 9/8/2011 9/8/2011 PD mg 800 mg /4/2011 4/10/2011 4/28/ WD mg 600 mg /4/2011 6/19/2014 6/19/2014 PD mg 800 mg /4/2011 7/10/ /10/2014 PD mg 800 mg /17/2011 3/24/2011 4/14/2011 AE mg 600 mg /18/ /24/ /25/2012 PD mg 600 mg /18/2011 9/27/2012 4/4/2013 PD mg 800 mg /17/2011 7/10/2011 EOS ND - AE mg 800 mg /29/2011 8/25/2011 8/25/2011 PD mg 600 mg /9/ /3/ /26/2013 PD mg 800 mg /23/2011 7/28/2011 EOS ND- PD mg 600 mg /14/2011 1/4/2012 1/5/2012 PD mg 600 mg /16/ /19/2013 1/16/2014 PD mg 800 mg /1/2012 3/21/2012 4/5/2012 AE mg 600 mg /22/2012 7/6/2012 7/12/2012 PD mg 600 mg /8/ /28/2014 ACTIVE mg 600 mg /22/ /28/2012 1/24/2013 PD mg 800 mg /22/2012 5/16/2013 5/16/2013 PD mg 800 mg /24/ /1/ /01/2013 PD mg 600 mg /23/2012 4/2/2013 4/4/2013 PD mg 600 mg /11/2012 8/14/ /14/2014 PD mg 600 mg /6/2012 4/17/ /17/2014 PD mg 800 mg (Re- Screen) 10/24/ /29/ mg 800mg /2/ /28/2014 ACTIVE mg 800 mg /10/2013 5/2/2014 6/19/2014 PD mg 400mg /29/2013 9/25/2014 9/25/2014 PD /3/ /28/2014 ACTIVE /3/ /28/2014 ACTIVE mg /21/2013 5/29/2014 5/29/2014 PD mg QD /27/2014 9/25/ /25/2014 PD mg
13 UPCC 18310: Vemurafenib in patients with Progressive PTC with BRAF V600E Key Eligibility Criteria Recurrent, unresectable or metastatic PTC BRAF V600 mutation positive by cobas RAI refractory Evidence of progression within 14 months Prior chemotherapy allowed Cohort 1: VEGFR2i-naive (n = 26) Cohort 2: VEGFR2i-pretreated (n = 25) Vemurafenib 960 mg bid until disease progression or unacceptable toxicity Primary end point: response rate per investigator in VEGFR2i-naive patients. Secondary end points: safety, duration of response, PFS, OS, PK, response rate in VEGFR2 inhibitor pretreated patients bid, 2 times a day; OS, overall survival; PFS, progression-free survival; PK, pharmacokinetics; VEGFR, vascular endothelial growth factor receptor; VEGFR2i, vascular endothelial growth factor receptor 2 inhibitor.
14 NO25530 Waterfall plot: Cohort 1 (TKI-naïve) # * Patients who had not discontinued treatment at time of data cut Cohort 1 (Tki naïve) BORR-evaluable 1 N= 26 # 1 patient missing baseline scan 9 Objective Responders 2 (Rate; 95% CI) Best Response (confirmed) Clinical Benefit Response (CR, PR, SD 6 mos) PR SD PD 10 (38.5%; ) 10 (38.5%; ) 15 (57.7%; ) 1 (3.8%: ) 19 (73.1%; ) 1 Patients with at least 2 post-bl tumor scan or PD/WD from for death or AE within first two cycles. 2 Confirmed PR/CR
15 PFS KM Curve: Cohort 1 Median PFS 18.2 mos (95% CI: )* *6 patients continue on therapy without progression 15
16 PFS KM Curve: Cohort 2 Median PFS: 8.9 months (95% CI: 5.4 NE)* *5 patients continue on therapy without progression 16
17 Cabozantinib: A Phase 1 Study Metastatic or surgically unresectable DTC Failed standard therapy Cabozantinib 140mg N=15 Adequate organ function and ECOG 0-2
18 UPCC 28313: Cabozanitib for patients with progressive RAI refractory DTC Eligibility criteria Metastatic, iodinerefractory thyroid cancer Life expectancy > 3 months ECOG PS 0-2 Good organ and bone marrow function n = 35 Primary endpoints cabozantinib RECIST 140mg daily PFS Response rate 18 patients accrued
19 Summary: RAI-Refractory DTC DTC is a vascular tumor that has been associated with increased activity of the MAPK pathways, and iodine-refractory patients have an average survival of 3 years Results of phase 3 trials with sorafenib (DECISION) were positive, This was approved in November 2013 and was the first agent since doxorubicin in Two additional phase 3 trials of lenvatinib (SELECT) and vandetanib (VERIFY) are ongoing Additional MKIs are also now in development, many of which target VEGFR-2, but also mtor, MEK, MET and BRAF and clinical trials will be needed to help us determine sequencing of approved agents and second- and third-line treatments going forward. DTC, differentiated thyroid cancer; MKI, multikinase inhibitor; mtor, mammalian target of rapamycin; RAI, radioactive iodine; VEGFR, vascular endothelial growth factor.
20 Trials on the Runway RIFTOS Study to determine what are the indicators for starting treatment for patients with DTC and who does the best and why Lenvatinib+everolimus in patients with DTC who progressed on lenvatinib alone Lenvatinib+everolimus For patients with MTC who have progressed on Cabozantinib and vandetanib
21 2014 / 2015 DTC Activities Summary Phase II Sorafenib in advanced thyroid cancer including ATC, DTC and MTC JCO Sorafenib Phase II reported early: met primary endpoint as of interim analysis Phase II: vemurafenib in BRAFmutated DTC Phase II: Vemurafenib in BRAF mutated DTC results ESMO 2013 Phase II: Cabretastatin in ATC Phase II: Everolimus+sorafenib in pts who progress on sorafenib Phase II: Cabozantinib in DTC Phase II: Everolimus+sorafenib: abstract submitted ASCO DECISION: Phase III sorafenib in DTC DECISION: Phase III results ASCO 2013 Sorafenib First FDA approved drug RAIrefractory DTC November 2013 EXAM: Phase III Cabozantinib in MTC EXAM: Phase III Cabozantinib in MTC results ASCO 2012 EXAM: FDA approves Cabozantinib in MTC- Nov 2012 SELECT: Phase III Lenvatinib in DTC Phase III: ASTRA Solumetanib Adjuvant study with RAI for high risk DTC SELECT: FDA Approves Lenvatinib in DTC February 2015 Phase III: VERIFY Vandetanib for DTC
22 Working together we can access new treatments and leverage resources. Coming together is a beginning; keeping together is progress; working together is success. -Henry Ford Thank You For Your Support!
23 Center for Rare Cancers What we hope to offer Cooperation among groups with different expertise Possible monthly meeting among Pis Sharing Industry Contacts to help facilitate access to trials and drugs Availability of translational research lab to facilitated translational work Full tissue IHC and Genetics Core available with staff who can help guide residents and techs Clinical Trial Research Staffing Economy of scale, sharing FTEs where needed Sharing GCP and centralized approach to decrease burden for clinical trial data collection Sharing insight and staff to aid in budget negotiations and regulatory Focus on capturing ALL eligible patients
24 And Personalized Therapy What we can offer Partnership with CPD to obtain solid tumor testing on all our patients Developing Basket trials aimed to catch patients with specific genetic and non-genetic pathway activation across tumor types. Ex, Trial of Tipifarnib for HRAS mutated solid tumors Partnership with Industry Partners with similar goals Genetech Novartis Exelixis Eisai Identify novel therapeutic markers for new targeted approaches Learn from other tumor types how targeted therapies may be applied in new contexts
25 Center for Rare Cancers and Personalized Therapies Initial Groups Sarcoma Neurooncology Gyn Onc Neuroendocrine Vet School Thyroid Mesothelioma Trials Cabozantinib in GBM and Other (mesothelioma) Loxo TRAK 1,2,3 inhibitor (solid tumors) Tipifarnib in HRAS mutated tumors (thyrid and other) More thyroid trials
26 University of Pennsylvania Thyroid Cancer Therapeutics Program Brose Translational Research Lab Mark Yarchoan MD Aaron Cohen MD Christian Squillante MD Waixing Tang, MD Zakkiyya Posey Thyroid Cancer Clinical Trials Unit Yvette Cruz, RN Carolyn Grande, RN, CRNP Kathleen Harlacker Thelma McCloskey Diane Foglia Experimental Therapeutics Program Andrea Troxel, PhD Peter O Dwyer, MD Pathology/Imaging Michael Feldman, MD, PhD Laurie Loevner, MD Thyroid Cancer Interest Group Susan Mandel, MD Ara Chalian, MD Douglas Fraker, MD Robert Lustig, MD Virginia LiVolsi, MD Zubair Baloch, MD Daniel Pryma MD Marcia Simpson Brose is a Damon Runyon-Siemens Clinical Investigator Many community endocrinologists who have referred their patients, and the patients who have agreed to participate in our trials
News Briefing: Highlights from the 2018 Multidisciplinary Head and Neck Cancers Symposium. Tuesday, February 13, 2018
News Briefing: Highlights from the 2018 Multidisciplinary Head and Neck Cancers Symposium Tuesday, February 13, 2018 News Briefing: Highlights from the 2018 Multidisciplinary Head and Neck Cancers Symposium
More informationObjectives. Novel Therapies for Advanced Thyroid Cancer. Disclosure Elements. Thyroid Cancer in the United States
Novel Therapies for Advanced Thyroid Cancer Marcia Brose MD PhD Department of Otorhinolaryngology: Head and Neck Surgery Department of Medicine, Division of Hematology/Oncology Abramson Comprehensive Cancer
More informationPromising New Treatments for Metastatic Differentiated and Medullary Thyroid Cancer. Marcia Brose MD PhD
Promising New Treatments for Metastatic Differentiated and Medullary Thyroid Cancer Marcia Brose MD PhD Department of Otorhinolaryngology: Head and Neck Surgery Department of Medicine, Division of Hematology/Oncology
More informationCarcinoma de Tiroide: Teràpies Diana
Carcinoma de Tiroide: Teràpies Diana Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology THYROID CANCER:
More informationNew Developments in Thyroid Cancer
New Developments in Thyroid Cancer Eric J. Sherman, MD Professor Vice-Chair for Clinical Operations Chief, Division of Head and Neck Surgery Departments of Otolaryngology, Radiation Oncology, and Immunology
More informationMANAGEMENT OF THYROID MALIGNANCIES
MANAGEMENT OF THYROID MALIGNANCIES Taofeek K. Owonikoko, MD, PhD Associate Professor Department of Hematology/Medical Oncology Winship Cancer Institute of Emory University Atlanta, GA 1 Disclosures Research
More informationMANAGEMENT OF REFRACTORY THYROID CANCER RAJKUMAR VENKATRAMANI, MD, MS RARE TUMORS PROGRAM TEXAS CHILDREN S HOSPITAL
MANAGEMENT OF REFRACTORY THYROID CANCER RAJKUMAR VENKATRAMANI, MD, MS RARE TUMORS PROGRAM TEXAS CHILDREN S HOSPITAL CONFLICTS OF INTEREST Policies and standards of the Texas Medical Association, the Accreditation
More informationAn update on systemic treatment of differentiated and medullary thyroid cancers: What to do after RAI
An update on systemic treatment of differentiated and medullary thyroid cancers: What to do after AI Disclosures: clinical trial support: - Exelixis, BI, Bayer, ECOG, TOG, GSK - Actogenix, Proacta, BMS,
More information2014 Debates and Didactics in Hematology and Oncology New treatments in the management of thyroid cancer
2014 Debates and Didactics in Hematology and Oncology New treatments in the management of thyroid cancer Taofeek K. Owonikoko, MD/PhD Associate Professor Department of Hematology/Medical Oncology Emory
More informationRadioiodine-refractory DTC
Oncology: Radioiodine-refractory DTC New Developments in Giuseppe COSTANTE, MD, Head, Endocrinology Clinic Institut Jules Bordet Université Libre de Bruxelles (U.L.B.) Targeted Therapies Targeted Treatments
More informationI. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationBackground. Capdevila J, et al. Ann Oncol. 2018;29(Suppl 8): Abstract 1307O. 1. Dasari A, et al. JAMA Oncol. 2017;3(10):
Efficacy of Lenvatinib in Patients With Advanced Pancreatic (pannets) and Gastrointestinal (ginets) WHO Grade 1/2 (G1/G2) Neuroendocrine Tumors: Results of the International Phase II TALENT Trial (GETNE
More information8/20/2017. Disclosures. Systemic Therapy for Thyroid Cancer: Who, When, and Why? Objectives. Thyroid cancer epidemiology
Disclosures Systemic Therapy for Thyroid Cancer: Who, When, and Why? Steven P. Weitzman, MD, FACE, ECNU The University of Texas MD Anderson Cancer Center Department of Endocrine Neoplasia and Hormonal
More informationHave Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationΗπατοκυτταρικός Καρκίνος Συστηματική Θεραπεία. Θωμάς Μακατσώρης Επίκ. Καθ. Παθολογίας-Ογκολογίας Ιατρική Σχολή Πανεπιστημίου Πατρών 11/5/2018
Ηπατοκυτταρικός Καρκίνος Συστηματική Θεραπεία Θωμάς Μακατσώρης Επίκ. Καθ. Παθολογίας-Ογκολογίας Ιατρική Σχολή Πανεπιστημίου Πατρών 11/5/2018 Advisory Board Disclosures Roche, Boeringer, Sanofi, Astra Zeneca,
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationMedullary Thyroid Carcinoma: New Therapies and Trials
Medullary Thyroid Carcinoma: New Therapies and Trials Matthew D. Ringel, MD Ralph W. Kurtz Chair and Professor of Medicine Director, Division of Endocrinology, Diabetes, and Metabolism The Ohio State University
More informationEvolution and Revolution of Radioiodine Refractory Differentiated Thyroid Cancer
Evolution and Revolution of Radioiodine Refractory Differentiated Thyroid Cancer Steven I. Sherman, M.D. Associate Vice Provost, Clinical Research Naguib Samaan Distinguished Professor Chair, Department
More informationLenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059]
Contains AIC Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059] Multiple Technology Appraisal Background and Clinical Effectiveness Lead team: Femi Oyebode
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More information3/29/2012. Thyroid cancer- what s new. Thyroid Cancer. Thyroid cancer is now the most rapidly increasing cancer in women
Thyroid cancer- what s new Thyroid Cancer Changing epidemiology Molecular markers Lymph node dissection Technical advances rhtsh Genetic testing and prophylactic surgery Vandetanib What s new? Jessica
More informationRiunione Monotematica A.I.S.F The future of liver diseases. HEPATIC NEOPLASMS The challenge for new drugs
Riunione Monotematica A.I.S.F. 2016 The future of liver diseases Milan 13 th -15 th October 2016 Centro Congressi Fondazione Cariplo HEPATIC NEOPLASMS The challenge for new drugs Massimo Iavarone Gastroenterology
More informationCabozantinib for medullary thyroid cancer. February 2012
Cabozantinib for medullary thyroid cancer February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationASCO 2011 Genitourinary Cancer
ASCO 2011 Genitourinary Cancer Expanding Options for Chronic Diseases? Walter Stadler, MD, FACP University of Chicago Disclosures (All Non-University &/or Financial Dealings with Potential, Real, or Perceived
More information12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval
12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval ARMANDO SANTORO Roma 10-6-2016 SORAFENIB APPROVAL 29 OCTOBER 2007 Marketing authorization
More informationRossella Elisei. Department of Endocrinology, University Hospital, Pisa, Italy
Rossella Elisei Department of Endocrinology, University Hospital, Pisa, Italy THYROID CANCER IS RARE TUMOR AND REPRESENTS ONLY 3.8% OF ALL HUMAN TUMORS All human cancer Thyroid cancer MOST FREQUENT CANCER
More informationA Review in the Treatment Options for Renal Cell Cancer
A Review in the Treatment Options for Renal Cell Cancer Ali McBride, PharmD, MS BCPS, BCOP Clinical Coordinator Hematology/Oncology Department of Pharmacy The University of Arizona Cancer Center RENAL
More informationInnovaciones en el tratamiento del ca ncer renal. Enrique Grande
Innovaciones en el tratamiento del ca ncer renal Enrique Grande The enriched inflammatory environment of RCC Chen Z, et al. Nat Rev Cancer 2014 Available agents are expanding across the three eras of arcc
More informationWhy was HOPE 205 a Positive After Years of Negative Studies?
Why was HOPE 205 a Positive After Years of Negative Studies? Prof. Dr. med. Viktor Grünwald Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation Why do we pursue combinations?
More informationResponse and resistance to BRAF inhibitors in melanoma
Response and resistance to BRAF inhibitors in melanoma Keith T. Flaherty, M.D. Massachusetts General Hospital Cancer Center Disclosures Roche/Genentech: consultant GlaxoSmithKline: consultant BRAF mutations
More informationFirst-line therapy for unresectable HCC:
ESMO GI Cancer Preceptorship 15 November 2017 Singapore First-line therapy for unresectable HCC: an oncologist s viewpoint Chiun Hsu, MD, PhD G raduate I n stitute of Oncology, National Taiwan Univers
More informationAn Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT )
An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967) J.M. Xu a, J. Li b, C.M. Bai c, N. Xu d, Z.W. Zhou e, Z.P. Li f, C.C. Zhou g, W. Wang h, J. Li
More informationWhen patients fail on molecular targeted therapy: what to do in 2013
When patients fail on molecular targeted therapy: what to do in 2013 For 3 rd APASAL HCC conference on 23 Nov 2013 Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong
More information2/21/2016. Cancer Precision Medicine: A Primer. Ovarian Cancer Statistics and Standard of Care in 2015 OUTLINE. Background
Cancer Precision Medicine: A Primer Rebecca C. Arend, MD Division of Gyn Oncology OUTLINE Background Where we are Where we have been Where we are going Targeted Therapy in Ovarian Cancer How to Individualized
More informationpresentation session & clinical Keith T. Flaherty, M.D. Abramson Cancer Center of the University of Pennsylvania
Melanoma: highlights from the oral presentation session & clinical science symposium at ASCO 2009 Keith T. Flaherty, M.D. Abramson Cancer Center of the University of Pennsylvania Abstracts to be discussed
More informationNew Agents for Head and Neck Cancer. Ezra Cohen, MD Associate Professor of Medicine University of Chicago Chicago, IL
New Agents for Head and Neck Cancer Ezra Cohen, MD Associate Professor of Medicine University of Chicago Chicago, IL Disclosure Dr. Cohen has the following relevant financial relationships with commercial
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for locally advanced or metastatic medullary thyroid cancer. December 2007
Vandetanib (Zactima) for locally advanced or metastatic medullary thyroid cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationClinical Policy: Lenvatinib (Lenvima) Reference Number: CP.CPA.251 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Lenvima) Reference Number: CP.CPA.251 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationEmerging Biomarkers of VEGF and mtor Inhibitors in 2015
Emerging Biomarkers of VEGF and mtor Inhibitors in 2015 Laurence Albiges Institut Gustave Roussy, France Fourteenth International Kidney Cancer Symposium Miami, Florida, USA November 6-7, 2015 www.kidneycancersymposium.com
More informationMalignant pleural Mesothelioma: A Year In Review
Malignant pleural Mesothelioma: A Year In Review Rabab Gaafar,MD Prof. Medical Oncology NCI Cairo University National Cancer Institute Conference 2015 ASCO news in Mesothelioma Introduction ASCO news second
More informationS4-NEW TREATMENT ALGORITHMS FOR SYSTEMIC THERAPY IN MANAGING AGGRESSIVE THYROID CANCER
S4-NEW TREATMENT ALGORITHMS FOR SYSTEMIC THERAPY IN MANAGING AGGRESSIVE THYROID CANCER Joshua Klopper and Bryan Haugen University of Colorado School of Medicine An important subset of patients with well
More informationMedical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationTyrosine Kinase Inhibition and Thyroid Cancer
Tyrosine Kinase Inhibition and Thyroid Cancer Loren Michel, M.D. Associate Attending Head and Neck Medical Oncology Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College NY, NY Financial
More informationMultiple Receptor Tyrosine Kinase Inhibitors
PHARMACY POLICY 5.01.534 Multiple Receptor Tyrosine Kinase Inhibitors Effective Date: Nov. 1, 2018 Last Revised: Oct. 9, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 5.01.517 Use of Vascular Endothelial
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationrisks. Therefore, perc agreed that the reimbursement criteria should match the eligibility criteria of the SELECT trial.
risks. Therefore, perc agreed that the reimbursement criteria should match the eligibility criteria of the SELECT trial. perc considered input from one patient advocacy group indicating that patients value
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationCirculating Tumor DNA in GIST and its Implications on Treatment
Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna
More informationHead & Neck/Thyroid. Recall the efficacy of promising investigational checkpoint inhibitors and EGFR inhibitors being evaluated in SCCHN.
Head & Neck/Thyroid C M E I n f o r m a t i o n TARGET AUDIENCE This activity is intended for medical oncologists, hematologyoncology fellows and other healthcare providers involved in the treatment of
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationBeyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy
Beyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy Oncogenic drivers in NSCLC Certain tumours arise as a result of aberrant activation
More informationClinical activity of BLU-667, a highly selective RET inhibitor, in advanced RET-altered thyroid cancers: updated results from the phase 1 ARROW study
Clinical activity of BLU-667, a highly selective RET inhibitor, in advanced RET-altered thyroid cancers: updated results from the phase 1 ARROW study Mimi I. Hu, Matthew Taylor, Lori Wirth, Viola Zhu,
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationSection 2 Original Policy Date 2013 Last Review Status/Date September 1, 2014
Policy Number 2.04.82 Molecular Markers in Fine Needle Aspirates of the Thyroid Medical Policy Section 2 Original Policy Date 2013 Last Review Status/Date September 1, 2014 Disclaimer Our medical policies
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationCOMETRIQ (cabozantinib) oral capsule
COMETRIQ (cabozantinib) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
COME HOME Thyroid Cancer pathway development worksheet, v9 April 13, 2015 Required Structured Data: Stage Staging Components Staging Date Histology Quality Measure(s): Staging (clinical or pathologic)
More informationAntiangiogenics are effective treatments in NETs
RENET: A randomized phase III trial comparing REgorafenib to placebo in patients with advanced, progressive, well-differentiated NEuroendocrine Tumors (NETs). Coordinators: Dr Julien Hadoux & Dr David
More informationNovel Molecular Molecular Therapies In Hepatocarcinoma Prof Eric
Novel Molecular Therapies In Hepatocarcinoma Prof. Eric Raymond Department of Médical Oncology Hôpital Beaujon, Clichy Université Paris 7 Denis Diderot INSERM-U728 eric.raymond@bjn.aphp.fr HCC is a highly
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationJon Trent, MD, PhD. Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center
Gastrointestinal Stromal Tumor GISTS 2010: After Standard of Care Jon Trent, MD, PhD Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center jtrent@mdanderson.org
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/36317 holds various files of this Leiden University dissertation. Author: Abdulrahman Hareedy, Randa Mostafa Title: Clinical and molecular studies on differentiated
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationPI3K/mTOR Dual Inhibitor
PI3K/mTOR Dual Inhibitor LY3023414 Courtney KD, et al 1 Drug Discovery Platform: Cancer Cell Signaling A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the
More informationHow does histology alter treatment? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy
How does histology alter treatment? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Targeting VHL/HIF in Clear Cell RCC VHL Bevacizumab (Antibody)
More informationSorafenib in metastatic radioactive iodine refractory differentiated thyroid cancer: A pilot study
MOLECULAR AND CLINICAL ONCOLOGY 2: 87-92, 2014 Sorafenib in metastatic radioactive iodine refractory differentiated thyroid cancer: A pilot study YANG LUO 1,2, YUANKAI SHI 1,2, PUYUAN XING 1,2, LIN WANG
More informationIpilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008
Ipilimumab ASCO Data Review and Discussion Webcast Monday, June 2, 2008 Slide 2 Forward Looking Statements Except for historical information, the matters contained in this slide presentation may constitute
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationOther Driver Mutations: cmet, B-RAF, RET, NTRK
Other Driver Mutations: cmet, B-RAF, RET, NTRK Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology and Medical Director, Memorial Cancer Institute Clinical Professor of Medicine Herbert Wertheim College
More informationNew strategies and future of target therapy in advanced kidney cancer
New strategies and future of target therapy in advanced kidney cancer VHL Gene Inactivation VHL Complex Disrupted VHL Protein HIF1-a, HIF2-a Accumulation VEGF PDGF TGF-α, CXCR4 Angiogenesis Endothelial
More informationRepurposed RET Inhibitors : poor RET coverage in humans MKI Approved Dose Toxicities
LOXO-292, a Potent, Highly Selective RET Inhibitor, in Multi-Kinase Inhibitor-Resistant RET Fusion-Positive Lung Cancer Patients with and without Brain Metastases Vamsidhar Velcheti 1, Todd Bauer 2, Vivek
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationSystemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works.
Systemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works. Arturo Loaiza-Bonilla, MD, FACP Assistant Professor of Clinical Medicine
More informationScientific Perspectives of Olaratumab Beyond the Approval Indication
Scientific Perspectives of Olaratumab Beyond the Approval Indication William D. Tap, MD Chief, Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center GEIS XVI International Symposium October
More informationResistance to anti-her2 therapies. Service d Oncologie Médicale
Resistance to anti-her2 therapies Pr David Khayat Service d Oncologie Médicale Groupe Hospitalier Pitié Salpêtrière -Paris Disclosure statment Trastuzumab in HER2+ MBC A major impact but resistance will
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationClinical Policy: Sorafenib (Nexavar) Reference Number: CP.PHAR.69 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Nexavar) Reference Number: CP.PHAR.69 Effective Date: 07.01.11 Last Review Date: 05.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for
More informationSecond - Line Debate: Axitinib
Second - Line Debate: Axitinib Alain Ravaud, MD PhD Bordeaux, France DISCLOSURES Member of Global, European and/or French advisory board in RCC and/or GU tumors for Pfizer, Novartis, GSK, Roche, BMS, Merck.
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationEvolution of Systemic Therapy Clinical Trials in VHL
Evolution of Systemic Therapy Clinical Trials in VHL Ramaprasad Srinivasan, M.D., Ph.D. Investigator and Head, Molecular Cancer Section Urologic Oncology Branch Center for Cancer Research National Cancer
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationThe Therapeutic Landscape in Advanced Renal Cell Carcinoma
The Therapeutic Landscape in Advanced Renal Cell Carcinoma Cora Sternberg, MD, FACP Chairman, Department of Medical Oncology San Camillo-Forlanini Hospital Rome, Italy What best describes the change in
More informationThe Met Pathway as a Target in RCC
The Met Pathway as a Target in RCC Harriet Kluger, M.D. Associate Professor Yale Cancer Center Disclosures pertinent to this presentation - none c-met Pathway (Biocarta) Rationale for c-met targeting in
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationA 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper)
A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper) Approved Kinase Inhibitors September 2014 Sponsored by PamGene www.pamgene.com The Kinase Activity Profiling
More informationPROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
More informationINITIAL RESULTS OF PHASE 1 STUDY OF DCC-2618, A BROAD-SPECTRUM KIT AND PDGFR
INITIAL RESULTS OF PHASE 1 STUDY OF DCC-2618, A BROAD-SPECTRUM KIT AND PDGFR INHIBITOR, IN PATIENTS (PTS) WITH GASTROINTESTINAL STROMAL TUMOR (GIST) BY NUMBER OF PRIOR REGIMENS. S George, M Heinrich, P
More information